Pluri (PLUR) Cash from Investing Activities (2010 - 2025)
Pluri (PLUR) posted quarterly Cash from Investing Activities of $2.7 million for Q4 2025, down 69.25% year-over-year from $8.6 million in Q4 2024, and down 30.96% quarter-over-quarter from $3.8 million in Q3 2025.
Pluri (PLUR) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Cash from Investing Activities for 16 consecutive years, with $2.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 69.25% year-over-year to $2.7 million; the TTM figure through Dec 2025 stood at $5.3 million (down 47.45% YoY), while the FY2025 annual figure was $8.0 million, down 24.17% from the prior year.
- Cash from Investing Activities slipped to $2.7 million in Q4 2025 per PLUR's latest filing, from $3.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $14.3 million in Q4 2021 and bottomed at -$23.8 million in Q1 2021.
- Historically, Cash from Investing Activities has averaged $1.4 million across 5 years, with a median of $3.4 million in 2025.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities tumbled 3635.31% — and 2025, when it surged 558.12%.
- Pluri's Cash from Investing Activities stood at $14.3 million in 2021, then tumbled by 95.33% to $669000.0 in 2022, then jumped by 485.8% to $3.9 million in 2023, then jumped by 120.59% to $8.6 million in 2024, then plunged by 69.25% to $2.7 million in 2025.
- Business Quant data shows PLUR's Cash from Investing Activities at $2.7 million in Q4 2025, $3.8 million in Q3 2025, and $3.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 2.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.66 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 3.03 Mn |
| Jun 30, 2025 | 3.03 Mn |
| Mar 31, 2025 | -4.23 Mn |
| Mar 31, 2025 | -4.23 Mn |
| Dec 31, 2024 | 8.65 Mn |
| Dec 31, 2024 | 8.65 Mn |
| Sep 30, 2024 | 585,000.00 |
| Sep 30, 2024 | 585,000.00 |
| Jun 30, 2024 | -4.81 Mn |
| Jun 30, 2024 | -4.81 Mn |
| Mar 31, 2024 | 5.67 Mn |
| Mar 31, 2024 | 5.67 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Sep 30, 2023 | 5.80 Mn |